SCHEDULE 13D/A: Activist Investor Whetstone Capital Nominates Two Directors to OptimizeRx Board

Whetstone Capital Advisors, holding an 8.2% stake in OptimizeRx Corporation, has formally nominated Andrew Carlson and John Fein for election to the company's Board of Directors at the upcoming 2025 annual meeting.

Summary

• Whetstone Capital Advisors, LLC (WCA) and David Atterbury (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13D concerning OptimizeRx Corporation.
• The Reporting Persons beneficially own 1,508,303 shares of OptimizeRx Common Stock, which represents 8.2% of the total outstanding shares.
• The acquisition of these shares was funded by approximately $7,557,310 from the working capital of private investment funds advised by WCA, excluding brokerage commissions.
• On March 6, 2025, WCA formally notified OptimizeRx Corporation of its intention to nominate Andrew Carlson and John Fein for election to the Board of Directors at the Issuer's 2025 annual meeting of stockholders.
• The Reporting Persons have engaged in, and plan to continue, communications with OptimizeRx regarding the composition of its Board and other related matters.

Sentiment

Score: 6

Explanation: The filing indicates an activist investor taking a significant stake and seeking board representation, which can be viewed positively by shareholders hoping for value creation through improved governance or strategic changes. However, it also introduces potential for boardroom conflict.

Positives

• The significant 8.2% stake acquired by Whetstone Capital Advisors indicates a strong conviction in OptimizeRx Corporation's potential value.
• The activist engagement by Whetstone Capital Advisors, including the nomination of new directors, could lead to enhanced corporate governance and strategic improvements, potentially unlocking greater shareholder value.
• The proposed director nominations suggest a proactive approach to improving board oversight and overall company performance.

Negatives

• The filing of a Schedule 13D by an activist investor implies a level of dissatisfaction with OptimizeRx Corporation's current management or strategic direction.
• The potential for a proxy contest or boardroom disagreements could introduce uncertainty and distraction for the company's operations and strategic focus.

Risks

• The Reporting Persons retain the flexibility to adjust their investment position, including purchasing additional shares, selling existing holdings, or engaging in hedging transactions, which could contribute to share price volatility.
• There is inherent uncertainty regarding the outcome of the director nominations and the possibility of a contested election, which could impact company stability.
• Significant changes resulting from the activist campaign could potentially disrupt current company operations or strategic plans.

Future Outlook

The Reporting Persons intend to continuously review their investment in OptimizeRx Corporation and may adjust their position by purchasing additional shares, selling existing holdings, or engaging in hedging transactions based on various factors including the Issuer's financial position, strategic direction, market conditions, and the outcome of discussions regarding Board composition.

Management Comments

• Whetstone Capital Advisors provided written notice to OptimizeRx Corporation of its intent to nominate Messrs. Andrew Carlson and John Fein for election to the Board at the Issuer's 2025 annual meeting of stockholders.

Industry Context

This filing exemplifies a broader trend of shareholder activism where significant investors acquire stakes to influence corporate strategy and governance, particularly in companies where they identify opportunities for value creation or perceive underperformance.

Management Changes

Corporate Governance

Legal Proceedings

• Neither the Reporting Persons nor their controlling entities, executive officers, or directors have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction during the last five years.

Related Party Transactions

• No contracts, arrangements, understandings, or relationships (legal or otherwise) among any Reporting Person or between such persons and any other person with respect to any securities of the Issuer were disclosed, including those related to call options, put options, security-based swaps, derivative securities, transfer or voting of securities, finder's fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through improved corporate governance and strategic initiatives driven by activist engagement.
• Current Board/Management: May face challenges to their existing positions and strategic plans due to the activist nominations and potential for a contested election.

Next Steps

• The OptimizeRx Corporation's 2025 annual meeting of stockholders will consider the nominated directors for election.
• Ongoing communications are expected between the Reporting Persons and OptimizeRx Corporation concerning Board composition and other strategic matters.
• The Reporting Persons may undertake future actions, including purchasing or selling additional shares, or engaging in hedging transactions, based on their ongoing review of the investment.

Key Dates

Keywords

OptimizeRx Corporation, Whetstone Capital Advisors, Schedule 13D, Shareholder Activism, Board Nomination, Corporate Governance, Investment Fund, Common Stock